This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
TXNDC9 / Thioredoxin domain-containing protein 9 · Western blot design guide
Design a Western Blot for TXNDC9
Source-linked TXNDC9 Western blot protocol options, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-TXNDC9 WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Evidence assembled October 2026 · For research use; verify linked source records and product datasheet before use
TXNDC9 Western Blot Experimental Design Guide
Expected bands, source-linked protocol options, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | ~26.5 kDa | |
| Gel | 12–15% (standard starting point) | |
| Positive control | Adrenal gland (IHC candidate; verify WB) +4 more | |
| Negative control | Cerebellum (IHC candidate; verify WB) |
Important caveats
Reasons your observed band may differ from the expected size.
| PTM | Phosphorylated | |
| Caveat | Phosphorylation-state controls | |
| Gene-set association | MSigDB C7 membership | |
| Isoform | 2 isoform(s) |
Section 1
Source-Linked TXNDC9 Western Blot Protocol Options
The A11467 protocol combines labelled catalog values with standard starting conditions. Published comparisons retain their own sample, reagent and detection scope.
| Sample / lysate | extracts of various cell lines, (catalog A11467) |
| Gel % | 12–15% (standard starting point) |
| Load | 20–30 µg total protein per lane; optimize for abundance (standard starting point) |
| Transfer | Short semi-dry transfer; verify retention (standard starting point) |
| Membrane | 0.45 µm PVDF (standard starting point) |
| Blocking | Blocking buffer: 3% nonfat dry milk in TBST (catalog A11467) |
| Primary antibody | A11467 · 1:3000 (catalog A11467) |
| Primary incubation | Overnight at 4 °C (standard starting point) |
| Secondary antibody | Goat Anti-Rabbit IgG, 1:10000 (catalog A11467) |
| Secondary incubation | 1 h at room temperature (standard starting point) |
| Wash | 3 × 5 min in TBST (standard starting point) |
| Detection | ECL (catalog A11467) |
Section 2
What Is the Expected TXNDC9 Western Blot Band Size?
TXNDC9 is predicted at 26.5 kDa; isoforms and phosphorylation are annotated, but their effects on migration have not been demonstrated.
| Band near 26.5 kDa | Consistent with the predicted TXNDC9 mass; confirm identity with a knockdown control. |
| Two discrete bands at different masses | Could reflect isoforms 1 and 2; their migration has not been established. |
| Doublet near 26.5 kDa | Could reflect phosphorylation at Ser188, Ser221 or Ser223; a visible shift is unproven. |
| Band in a cytoplasmic or nuclear fraction | Consistent with the reported locations of TXNDC9. |
💡Expected TXNDC9 appearanceTXNDC9 has a predicted mass of 26.5 kDa, but no empirical band size is supplied; confirm any candidate band with knockdown and an independent antibody.
| Predicted TXNDC9 mass | Sets a 26.5 kDa sequence-based reference, not a validated migration position. |
| Alternative splicing | Produces isoforms 1 and 2, whose mass difference is not supplied. |
| Isoform 1 | Has no supplied isoform-specific mass or migration position. |
| Isoform 2 | May differ in size from isoform 1, but its relative size is not supplied. |
| Situation | Likely cause | Next action |
|---|---|---|
| No band in lysate | TXNDC9 may be below detection in the sampled lysate. | Check lysate loading and assay sensitivity; test a cytoplasmic fraction. |
| Band higher than expected | Identity or migration of the band is unverified. | Compare with TXNDC9 knockdown and an independent antibody. |
| Band lower than expected | An isoform is possible, but isoform migration is unknown. | Test whether the band decreases after TXNDC9 knockdown. |
| Multiple bands | Isoforms 1 and 2 are annotated; their band positions are unknown. | Check each band with knockdown and an independent antibody. |
| Weak or no signal | The sampled fraction may contain little TXNDC9. | Check loading and compare cytoplasmic and nuclear fractions. |
Experiment evidence
Western blot images showing TXNDC9 band
A11467 · TXNDC9
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for TXNDC9 Western blot
🧪HPA-IHC candidate guidance (verify in WB): For positive controls for TXNDC9 in Western blot, you can use adrenal gland lysate, where HPA reports medium expression.
Positive control: Adrenal gland (IHC candidate; verify WB)
Negative control: Cerebellum (IHC candidate; verify WB)
Loading controls: Run GAPDH, β-actin, and a total-protein stain such as Ponceau alongside the samples.
⚠️Feasibility: An intracellular positive lysate and an HPA not-detected tissue are available, though the negative should be verified experimentally.
HPA tissue expression evidence for TXNDC9
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Higher expression tissues · candidate positive controls from IHC
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | glandular cells | Medium | Protein (IHC) | HPA → |
| Appendix | glandular cells | Medium | Protein (IHC) | HPA → |
| Bone marrow | hematopoietic cells | Medium | Protein (IHC) | HPA → |
| Breast | glandular cells | Medium | Protein (IHC) | HPA → |
| Bronchus | respiratory epithelial cells | Medium | Protein (IHC) | HPA → |
Lower expression tissues · IHC evidence, not confirmed WB-negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Cerebellum | cells in granular layer | Not detected | Protein (IHC) | HPA → |
| Liver | cholangiocytes | Not detected | Protein (IHC) | HPA → |
| Adipose tissue | adipocytes | Low | Protein (IHC) | HPA → |
| Caudate | neuronal cells | Low | Protein (IHC) | HPA → |
| Heart muscle | cardiomyocytes | Low | Protein (IHC) | HPA → |
Section 3
Advanced TXNDC9 Western Blot Tips
Deeper troubleshooting and optimisation questions for TXNDC9, answered from its protein features.
Where should the main TXNDC9 band appear?
Band shift · The supplied predicted mass is 26.5 kDa for the 226-residue canonical sequence. No observed band position is available, so compare your band with a molecular-weight marker without treating 26.5 kDa as an exact migration position.
Could TXNDC9 isoforms produce different bands?
Isoforms · UniProt lists isoforms 1 and 2. In isoform 2, canonical residues 188–226 are replaced by a single arginine, so it may migrate below the canonical protein. An antibody against that replaced region may miss isoform 2; check its epitope before assigning bands.
For a combined TXNDC9 measurement, choose an antibody epitope shared by both isoforms and account for any separately resolved bands. For isoform-specific measurement, verify epitope coverage: isoform 2 replaces canonical residues 188–226 with arginine.
For a combined TXNDC9 measurement, choose an antibody epitope shared by both isoforms and account for any separately resolved bands. For isoform-specific measurement, verify epitope coverage: isoform 2 replaces canonical residues 188–226 with arginine.
Which TXNDC9 phosphorylation sites matter when interpreting bands?
PTM · UniProt lists phosphoserines at canonical positions 188, 221 and 223. All three positions fall within the segment replaced in isoform 2. Phosphorylation is worth considering when examining band patterns, but these annotations alone do not establish a visible shift.
Phosphoserines are annotated at canonical positions 188, 221 and 223, but their presence alone cannot explain a particular apparent-mass difference. Compare the band against a molecular-weight marker and confirm its identity before attributing slower migration to phosphorylation.
Phosphoserines are annotated at canonical positions 188, 221 and 223, but their presence alone cannot explain a particular apparent-mass difference. Compare the band against a molecular-weight marker and confirm its identity before attributing slower migration to phosphorylation.
Does this guide establish induction of TXNDC9?
Induction · No general induction response is established by this guide. A pathway or gene-set association is not evidence of induction in a particular specimen. Verify the relevant treatment and control in a target-specific experiment.
How should transfer be checked for TXNDC9?
Transfer · Standard workflow guidance: verify transfer efficiency for the intended target size before interpreting a weak signal. Use total-protein assessment and optimize transfer for the membrane, gel and apparatus; the labelled catalog values take precedence.
How should blocking be optimized?
Blocking · Standard workflow guidance: follow the A11467 datasheet where specified. Otherwise compare 5% milk or 5% BSA in TBST; for a phospho-specific assay start with BSA. Optimize background and specific signal with matched controls.
How should TXNDC9 be quantified?
Quantitation · Standard workflow guidance: quantify only a validated target band within the linear exposure range. Use consistent sample preparation and loading, retain biological replicates, and avoid interpreting saturation or loading differences as regulation.
Can TXNDC9 appear in different cellular fractions?
Interpretation · UniProt lists cytoplasm, nucleus, centrosome and midbody locations. A signal in more than one fraction can therefore be consistent with its annotated distribution. Assess fraction purity before interpreting differences in band intensity as changes in TXNDC9 abundance.
TXNDC9 forms ternary complexes with the TCP1 chaperonin complex. That interaction makes a high-mass species worth investigating, but the feature alone does not identify a band or show that the complex survives Western-blot sample preparation. Confirm TXNDC9 identity before assigning it to the complex.
TXNDC9 forms ternary complexes with the TCP1 chaperonin complex. That interaction makes a high-mass species worth investigating, but the feature alone does not identify a band or show that the complex survives Western-blot sample preparation. Confirm TXNDC9 identity before assigning it to the complex.
Boster reagents
TXNDC9 Western Blot Antibodies
Catalog antibodies with Western blot application and product-specific WB images. Evaluate suitability with the reported sample, controls and experimental conditions.
Real WB data
Anti-TXNDC9 Antibody
Cat # A11467
The catalog reports one anti-TXNDC9 antibody for Western blot, A11467, with reported Human, Mouse, and Rat reactivity. Its WB image caption describes extracts from various cell lines, but does not identify the cell lines or establish species-specific WB validation.
Which to pick: A11467 is the only listed option and has a WB image. The reported blot used 25 µg protein per lane and a 1:3000 primary dilution; check suitability for your sample species separately.
Source: BosterBio TXNDC9 gene-info card — filtered to Western-blot-capable antibodies; each card shows that product's actual WB validation figure.
References
- UniProt Consortium. UniProt entry O14530.
- Human Protein Atlas. TXNDC9 tissue expression.
- PMC9073845 — target-verified WB comparison
- PMC6208382 — target-verified WB comparison
- PMC5463158 — target-verified WB comparison